Cost-Effectiveness of Conjugate Meningococcal Vaccination Strategies in the United States
Authors:
- Colin W. ShepardCSColin W. Shepard
- the ABCs TeamTTthe ABCs Team
- 1 May 2005
- journal article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 115 (5) , 1220-1232
Abstract
Context. The US Food and Drug Administration approved a meningococcal conjugate A/C/Y/W-135 vaccine (MCV-4) for use in persons aged 11 to 55 years in January, 2005; licensure for use in younger age groups is expected in 2 to 4 years.Keywords
This publication has 51 references indexed in Scilit:
- An Economic Analysis of the Current Universal 2-dose measles-mumps-rubella Vaccination Program in the United StatesThe Journal of Infectious Diseases, 2004
- Opportunities for Control of Meningococcal Disease in the United StatesAnnual Review of Medicine, 2004
- Safety, Reactogenicity, and Immunogenicity of a Tetravalent Meningococcal Polysaccharide–Diphtheria Toxoid Conjugate Vaccine Given to Healthy AdultsThe Journal of Infectious Diseases, 2002
- Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysisAmerican Journal of Preventive Medicine, 2002
- Complications of Meningococcal Disease in College StudentsClinical Infectious Diseases, 2001
- Overall cost in the treatment of otitis mediaThe Pediatric Infectious Disease Journal, 1997
- Cost-effectiveness of a routine varicella vaccination program for US children1994
- FUNCTIONAL LIMITATION AFTER MAJOR TRAUMA1994
- Quality of life in bone tumor patients comparing limb salvage and amputation of the lower extremityJournal of Surgical Oncology, 1992
- Complications and sequelae of meningococcalinfections in childrenThe Journal of Pediatrics, 1981